Venus Concept Inc.
VEROOTCHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $64.8M | $76.4M | $99.5M | $105.6M | $78.0M | $110.4M |
| Operating income | −$27.2M | −$28.3M | −$34.9M | −$14.8M | −$67.9M | −$30.3M |
| Net income | −$47.0M | −$37.3M | −$43.7M | −$23.0M | −$81.7M | −$40.6M |
| Total assets | $68.2M | $93.7M | $125.4M | $157.4M | $160.5M | $191.1M |
| Total liabilities | $65.3M | $107.1M | $116.6M | $115.8M | $116.8M | $114.4M |
| Equity | $2.4M | −$14.0M | $8.1M | $40.9M | $44.2M | $74.2M |
| EPS (diluted) | $-71.21 | $-68.47 | $-9.94 | $-0.42 | $-2.33 | $-4.77 |
| Shares out. | 6.4M | 80.0M | 64.0M | 54.0M | 32.2M | 40.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −41.9%
- Net margin
- −72.5%
- Return on equity
- −1983.8%
- Return on assets
- −68.9%
- Return on capital (ROCE)
- −71.7%
- Liabilities / assets
- 95.8%
- Debt / equity
- 27.58×
- Book value / share
- $0.37
- Revenue growth (YoY)
- −15.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -15.66distress
- Accruals / assets
- −52.7%clean
- Beneish M-Score
- -5.27normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ew Healthcare Partners, L.P.Activist (13D)Apr 1, 2026
- Madryn Asset Management, LpActivist (13D)Mar 30, 2026
- Intracoastal Capital, LlcPassive (13G)Jun 13, 2025
- Orca Capital AgPassive (13G)Jun 11, 2025
- Healthquest Partners Ii, L.P.Activist (13D)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Mar 31, 2026 | 13,297 | 1.0 | -5.2% |
| Mar 13, 2026 | 14,022 | 1.0 | -12.3% |
| Feb 27, 2026 | 15,981 | 1.0 | -43.6% |
| Feb 13, 2026 | 28,328 | 1.0 | -61.1% |
| Jan 30, 2026 | 72,826 | 1.0 | -57.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementFeb 3, 2026
- Entered a material agreement · Delisting / listing-standard notice · Other material eventJan 21, 2026
- Entered a material agreementJan 7, 2026
- Entered a material agreementDec 2, 2025
- Results of operations · Other material eventNov 13, 2025
- Entered a material agreementOct 31, 2025
- Entered a material agreement · Unregistered equity sale · Amended charter or bylaws · Regulation FD disclosureOct 2, 2025
- Entered a material agreement · Director / officer changeSep 22, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- DApr 9, 2026
- SCHEDULE 13D/AApr 1, 2026
- SCHEDULE 13D/AMar 30, 2026
- 4Mar 30, 2026
- SCHEDULE 13D/AMar 27, 2026
- 4Mar 27, 2026
- SCHEDULE 13D/AMar 18, 2026
- SCHEDULE 13D/AMar 17, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
- EFFECTFeb 10, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.